Vimarsana
Biggest News Aggregation in the World

Bio Contact News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Bio Contact. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Bio Contact Today - Breaking & Trending Today

BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024 - Vimarsana News

BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024

PALO ALTO, Calif., June 03, 2024 -- BridgeBio Pharma, Inc. , a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that members of its management team, along...

G1 Therapeutics and Pepper Bio Announce Global (Excluding - Vimarsana News

G1 Therapeutics and Pepper Bio Announce Global (Excluding

G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib ...

G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib - Vimarsana News

G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib

- Pepper Bio will Gain Exclusive Rights for the Clinical Development, Regulatory Submissions, and Commercialization of Lerociclib in the US, Europe, Japan, and All Other Global Markets Excluding...

INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay - Vimarsana News

INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay

Boca Raton, Florida, April 23, 2024 --  INmune Bio, Inc.  , a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight...

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Vimarsana News

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., April 10, 2024 -- BridgeBio Pharma, Inc. , a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on April 5, 2024, the...